What does this research mean for the field?

CRISPR-based gene-editing therapy, specifically exagamglogene autotemcel, provides a clinically validated, curative-intent treatment for severe hemoglobinopathies, though its successful clinical integration requires rigorous multidisciplinary care, specialized infrastructure, and long-term surveillance. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the clinical implementation, therapeutic outcomes, and delivery barriers of CRISPR-based gene editing for hemoglobinopathies and emerging oncology applications.

August 22, 2026JCO Oncology Practice

Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies

View Full Paper

Ask AI

Bookmark

Authors

MHMiza Salim HammoudCleveland Clinic RHRabi HannaCleveland Clinic

Discussion

Member takes

Implication

Review demonstrates durable efficacy of CRISPR-Cas9 therapy in sickle cell disease and beta-thalassemia, highlighting clinical delivery hurdles and oncology expansion.

Key Points

To review the clinical implementation, therapeutic outcomes, and delivery barriers of CRISPR-based gene editing for hemoglobinopathies and emerging oncology applications.
Evaluated ex vivo CRISPR-Cas9 gene editing of autologous CD34-positive hematopoietic stem and progenitor cells engineered to reactivate fetal hemoglobin.
Synthesized clinical requirements including stem cell mobilization, centralized manufacturing, pharmacokinetic-guided myeloablative conditioning, and investigational cancer trial data.
Achieved durable freedom from severe vaso-occlusive crises in sickle cell disease and sustained transfusion independence in transfusion-dependent β-thalassemia without risk of graft rejection or graft-versus-host disease.
Identified critical implementation challenges including conditioning-related toxicity, stem cell collection constraints, substantial therapy costs, and access inequities.
Demonstrated early investigational feasibility in oncology for relapsed or refractory B-cell malignancies, T-cell malignancies, acute myeloid leukemia, multiple myeloma, and solid tumors.

Cite This Study

Hammoud et al. (2026) studied this question.

synapsesocial.com/papers/6a895effca7ade938187d4d1 https://doi.org/10.1200/op-26-00479

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates durable efficacy of CRISPR-Cas9 therapy in sickle cell disease and beta-thalassemia, highlighting clinical delivery hurdles and oncology expansion.

Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider